Mathematical and experimental analysis of localization of anti-tumour antibody-enzyme conjugates

British Journal of Cancer

Volumn 80, Issue 11, 1999, Pages 1747-1753

  Jackson, T L ^a   Lubkin, S R ^a   Siemers, N O ^b   Kerr, D E ^b   Senter, P D ^b   Murray, J D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; CAPILLARY; CONJUGATE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BETA-LACTAMASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; KINETICS; MELANOMA; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASMS; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032812916     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690592     Document Type: Article

References (23)

1. Bagshawe KD and Begent RHJ (1996) First clinical experience with ADEPT. Adv Drug Delivery Rev 22: 365-367
2. Baxter LT and Jain RK (1989) Transport of fluid and macromolecoles in tumors. I. role of interstitial pressure and connection. Microvasc Res 37: 77-104
3. Baxter LT and Jain RK (1991a) Transport of fluid und macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 41: 5-23
4. Baxter LT and Jain RK (1991b) Transport of fluid and macromolecules in tumors. IV. a microscopic model of the perivascular distribution. Microvasc Res 41: 252-272
5. Baxter LT and Jain RK (1996) Pharmacokinetics analysis of the microscopic distribution of enzyme-conjugated antbodies and prodrugs: comparison with experimental data. Br J Cancer 73: 447-456
6. Baxter LT, Yuan F and Jain RK (1992) Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 52: 5838-5844
7. Rosslet K, Czech J and Hoffmann D (1994) Tumor selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 54: 2152-2159
8. Eccles SA, Court WJ, Box GA, Dean CJ, Melton GR and Springer CJ (1994) Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erb-b2 p185. Cancer Res 54: 5171-5177
9. Gerlowski LE and Jain RK (1986) Microvascular permeability of normal and neoplastic tissues. Microvas Res 31: 288-305
10. Kerr DE, Schreiber GJ, Vrudhula BM, Svensson HP, Hellstrom KE and Senter PD (1995) Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res 55: 3558-3563
11. Krogh A (1919) The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J of Physiol 52: 409-415
12. Melton RG and Sherwood KF (1996) Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 88: 153-165
13. Meyer DL, Jungheim LN, Law KL, Mikolajezyk SD, Shepherd TA, Mackensen DG, Briggs SL and Starling JJ (1992) Site-specific proidrug activation by antibody-β-lactamase conjugates: regression and long term growth inhibition of human colon carcinoma xenograft models. Cancer Res 53: 3956-3963
14. Niculescu-Duvaz I and Springer CJ (1996) Antibody-directed enzyme prodrug therapy (ADEPT): a targeting strategy in cancer chemotherapy. Curr Med Chem 2: 687-706
15. Nugent LJ and Jain RK (1984) Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44: 238-244
16. O'Callaghan DE, Morris A, Kirby S and Shingler AH (1972) Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother 1: 283-288
17. Ptelersz GA, Rowland A, Smyth MJ and McKenzie IF (1994) Chemoimmuno-conjugates for the treatment of cancer. Adv Immunol 56: 301-387
18. Senter PD and Svensson HP (1997) A summary of monoclonal antibody enzyme/prodrug combinations. Adv Drug Delivery Rev 22: 341-349
19. Senter PD, Wallace PM, Svensson HP, Vrudhula VM, Kerr DE, Hellstrom I and Hellstrom KE (1993) Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chem 4: 3-9
20. Siemers NO, Kerr DE, Yarnold S, Stebbins M, Vrudhula VM, Hellstrom I, Hellstrom KE and Senter PD (1997) L-49-sfv-β-lactamase, a single chain anti-p97 antibody fusion protein. Bioconjugate Chem 8: 510-519
21. Springer CJ, Bagshawe KD, Sharma SK, Seurle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF and Melton RG (1991) Abalation of human choriocarcinona xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 27: 1361-1366
22. Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Wallace PM and Senter PD (1993) In vitro and in vivo activities of doxonibicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Canceer Res 55: 2357-2365
23. Wallace PM, MacMaster JF, Smith V, Kerr DE, Senter PD and Cosand WL (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54: 2719-2723